{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:05:55Z","timestamp":1760853955191},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.biopha.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T18:16:53Z","timestamp":1492193813000},"page":"665-669","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis"],"prefix":"10.1016","volume":"90","author":[{"given":"Alberto","family":"Mazza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella Paola","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyelle M.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Bregola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo","family":"Contatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Cappello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Ramazzina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Rubello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2017.04.008_bib0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.04.008_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/HJH.0b013e32834000be","article-title":"The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials","volume":"29","author":"Czernichow","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2017.04.008_bib0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCULATIONAHA.105.542290","article-title":"Antihypertensive medication use among US adults with hypertension","volume":"113","author":"Gu","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2017.04.008_bib0020","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","volume":"31","author":"Mancia","year":"2013","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.biopha.2017.04.008_bib0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1524-4733.2002.54142.x","article-title":"Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?","volume":"5","author":"Mullins","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.biopha.2017.04.008_bib0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0277-9536(96)00394-2","article-title":"Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions","volume":"45","author":"Grabowski","year":"1997","journal-title":"Soc. Sci. Med."},{"issue":"1","key":"10.1016\/j.biopha.2017.04.008_bib0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1524-4733.2003.00212.x","article-title":"How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance","volume":"6","author":"Guo","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.biopha.2017.04.008_bib0040","unstructured":"http:\/\/bur.regione.veneto.it\/BurvServices\/pubblica\/DettaglioDgr.aspx?id=289237."},{"key":"10.1016\/j.biopha.2017.04.008_bib0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","article-title":"Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants","volume":"389","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.04.008_bib0050","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1001\/jama.291.15.1850","article-title":"Economic implications of evidence-based prescribing for hypertension: can better care cost less?","volume":"291","author":"Fischer","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2017.04.008_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320310370852","article-title":"Angiotensin II type 1 receptor blockers: class effects versus molecular effects","volume":"12","author":"Miura","year":"2011","journal-title":"J. Renin. Angiotensin. Aldosterone Syst."},{"key":"10.1016\/j.biopha.2017.04.008_bib0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/A:1009717702189","article-title":"Effects of angiotensin II antagonists in comparison to ACE inhibitors in patients with heart failure due to systolic left ventricular dysfunction","volume":"3","author":"Pitt","year":"1999","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.biopha.2017.04.008_bib0065","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacc.2003.11.029","article-title":"Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study","volume":"43","author":"Julius","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2017.04.008_bib0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2017.04.008_bib0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mce.2008.06.006","article-title":"Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism","volume":"302","author":"Van Liefde","year":"2009","journal-title":"Mol. Cell Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2017.04.008_bib0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","article-title":"The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases","volume":"38","author":"Abraham","year":"2015","journal-title":"Drug Saf."},{"issue":"26","key":"10.1016\/j.biopha.2017.04.008_bib0085","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/eurheartj\/eht333","article-title":"Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis","volume":"35","author":"Makani","year":"2014","journal-title":"Eur. Heart J."},{"issue":"221","key":"10.1016\/j.biopha.2017.04.008_bib0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijcard.2016.06.115","article-title":"A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients","volume":"15","author":"Kourlaba","year":"2016","journal-title":"Int. J. Cardiol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217315214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217315214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T17:56:12Z","timestamp":1535910972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217315214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":18,"alternative-id":["S0753332217315214"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.04.008","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}